ER POSITIVE BREAST CANCER
Clinical trials for ER POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets rare cancer mutation in early trial
Disease control OngoingThis early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New study explores letrozole's effects on breast cancer before surgery
Disease control OngoingThis study tests the drug letrozole in postmenopausal women with early-stage ER+ breast cancer. Participants take letrozole for 4 to 24 weeks before surgery to see how the tumor changes and to check if they take the medication as prescribed. The goal is to improve treatment for t…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Promising breast cancer drug trial pulled before starting
Disease control TerminatedThis study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Danish Breast Cancer Cooperative Group • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug combo aims to stop breast cancer from coming back
Disease control OngoingThis Phase 2 trial is testing whether adding the drug ribociclib (Kisqali) to standard hormone therapy can improve outcomes for people with early-stage ER-positive breast cancer. The study involves 120 participants and focuses on clearing cancer DNA from the blood. The goal is to…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo shows promise in shrinking breast tumors before surgery
Disease control OngoingThis study tests a combination of two drugs, lenvatinib and letrozole, given before surgery to postmenopausal women with a common type of breast cancer (hormone receptor positive). The goal is to see if the drugs can shrink the tumor enough to improve surgical outcomes. About 40 …
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Blood test may help doctors switch cancer treatment earlier
Knowledge-focused OngoingThis study looks at whether a blood test that tracks tumor DNA (ctDNA) can help doctors switch treatments earlier in people with metastatic breast cancer. The goal is to see if acting on a molecular signal of progression, before symptoms or scans show it, can keep the cancer unde…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC